Paratek Pharmaceuticals (NASDAQ: PRTK) is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments.
Paratek Pharmaceuticals is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. We focus on drugs that target infectious disease and other difficult to treat conditions.
Our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. The Food and Drug Administration (FDA) granted omadacycline a Qualified Infectious Disease Product (QIDP) designation and completed two special protocol assessments for its Phase 3 clinical trial program.
To empower physicians with the tools they need to create better stories. We’re on a mission to help turn every day decisions into everyday triumphs for patients with diseases that are not responsive to current treatments.
